More than 75% of eligible people not using migraine preventive therapy

An interim analysis of the Chronic Migraine Epidemiology and Outcomes-International (CaMEO-I) study has found that although the use of preventive medication for migraine more than doubled from 2012 to 2021, over 75% of people with migraine who are eligible are not taking preventive therapy.

In the CaMEO-1 study, researchers from the Albert Einstein College of Medicine, Vedanta Research and AbbVie Inc. performed a cross-sectional, web-based survey of individuals in Canada, France, Germany, Japan, UK, and USA, who met criteria for migraine consistent with the International Classification of Headache Disorders, 3rd edition.